Publications

Included here are publications by faculty members intimately involved with the Pediatric Trials Network, many of which stem from studies conducted by the network. Some of the publications are accessible to the public; others require a subscription to the journal in which the article was published. If you are unable to view an article, ask your physician if he or she can access the article.

Pediatric Trials Network/Best Pharmaceuticals for Children Act Results

  1. A Population-Based Pharmacokinetic Model Approach to Pantoprazole Dosing for Obese Children and Adolescents.
    Shakhnovich V, Smith PB, Guptill J, James L, Collier D, Wu H, Livingston C, Zhao J, Kearns G, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Pediatric Drugs • August 2018
    Pubmed PMID: 30097906
  2. Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children.
    Hornik CP, Gonzalez D, van den Anker J, Atz AM, Yogev R, Poindexter BB, Ng KC, Delmore P, Harper BL, Melloni C, Lewandowski A, Gelber C, Cohen-Wolkowiez M, Lee JH; Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Journal of Clinical Pharmacology • April 2018
    Pubmed PMID: 29677389
  3. Comparative Analysis of Ampicillin Plasma and Dried Blood Spot Pharmacokinetics in Neonates.
    Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Blackford M, Yogev R, James LP, Melloni C, Harper B, Mitchell J, Benjamin DK Jr, Boakye-Agyeman F, Cohen-Wolkowiez M
    Therapeutic Drug Monitoring • February 2018
    PMCID: PMC5764797
  4. A Pharmacokinetic Model for Amiodarone in Infants Developed from an Opportunistic Sampling Trial and Published Literature Data.
    Dallefeld SH, Atz AM, Yogev R, Sullivan JE, Al-Uzri A, Mendley SR, Laughon M, Hornik C, Melloni C, Harper B, Lewandowski A, Mitchell J, Wu H, Green TP, Cohen-Wolkowiez M.
    Journal of Pharmacokinetics and Pharmacodynamics February 2018
    Pubmed PMID: 29435949
  5. Obese Children Require Lower Doses of Pantoprazole than Nonobese Peers to Achieve Equal Systematic Drug Exposures.
    Shakhnovich V, Smith PB, Guptill J, James L, Collier D, Wu H, Livingston C, Zhao J, Kearns G; Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    The Journal of Pediatrics • February 2018, volume 193, pages 102-108.
  6. A Weight Estimation Strategy for Preterm and Full-Term Infants.
    Abdel-Rahman S, Paul I, Delmore P, James L, Fearn L, Atz A, Poindexter B, Al-Uzri A, Lewandowski A, Harper B, Smith PB; Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Global Pediatric Health December 2017, volume 4, pages 1-9.
  7. An Anthropometric Survey of U.S. Preterm and Full-Term Neonates.
    Abdel-Rahman S, Paul I, Delmore P, James L, Fearn L, Atz A, Poindexter B, Al-Uzri A, Lewandowski A, Harper B, Smith PB; Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Annals of Human Biology November 2017, volume 44, issue 8, pages 678-686.
    Pubmed PMID: 29037091.
  8. Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin‐Tazobactam Safety in Infants.
    Salerno S, Hornik CP, Cohen‐Wolkowiez M, Smith PB, Ku LC, Kelly MS, Clark R, Gonzalez D, Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.
    The Pediatric Infectious Disease Journal • September 2017, volume 36, issue 9, pages 855‐859.
    PMCID: PMC5555808
  9. Population Pharmacokinetics and Exploratory Pharmacodynamics of Lorazepam in Pediatric Status Epilepticus.
    Gonzalez D, Chamberlain JM, Guptill JT, Sullivan JE, Cohen‐Wolkowiez M, Harper B, Martz K, Capparelli EV; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.
    Clinical Pharmacokinetics • August 2017, volume 56, issue 8, pages 941‐951.
    PMCID: PMC5466505
  10. Respiratory Support for Very Low Birth Weight Infants Receiving Dexamethasone.
    Virkud YV, Hornik CP, Benjamin DK, Laughon MM, Clark RH, Greenberg RG, Smith PB.
    The Journal of Pediatrics • April 2017, volume 183, pages 26-30.
    PMCID: PMC5368005
  11. Safety of High‐Dose Acyclovir in Infants with Neonatal Herpes Simplex Virus Infections.
    Ericson JE, Gostelow M, Autmizguine J, MD, Hornik CP, Clark RH, Benjamin DK, Smith PB.
    The Pediatric Infectious Disease Journal • April 2017, volume 36, issue 4, pages 369‐37.
    PMCID: PMC5348260
  12. Pharmacokinetics of Clindamycin in Obese and Non‐obese Children.
    Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, Anand R, Martz K, Berezny K, Benjamin DK Jr, Smith PB, Cohen‐Wolkowiez M, Watt K, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.
    Antimicrobial Agents and Chemotherapy • March 2017, volume 61, issue 4.
    PMCID: PMC5365720
  13. Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit.
    Ku LC, Zimmerman K, Benjamin DK, Clark RH, Hornik CP, Smith PB; Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.
    Pediatric Cardiology January 2017, volume 38, issue 1, pages 155-161.
    Pubmed PMID: 27826711; PMCID: PMC5288129 [Free access copy available on January 1, 2018]
  14. Effectiveness of Granulocyte Colony-Stimulating Factor in Hospitalized Infants with Neutropenia.
    Lee JA, Sauer B, Tuminski W, Cheong J, Fitz-Henley J 2nd, Mayers M, Ezuma-Igwe C, Arnold C, Hornik CP, Clark RH, Benjamin DK Jr, Smith PB, Ericson JE; Best Pharmaceuticals for Children Act—Pediatric Trials Network Steering Committee.
    American Journal of Perinatology September 2016
    Pubmed PMID: 27649291
  15. Fluconazole Prophylaxis for the Prevention of Candidiasis in Premature Infants: A Meta-analysis Using Patient-level Data.
    Ericson JE, Kaufman DA, Kicklighter SD, Bhatia J, Testoni D, Gao J, Smith PB, Prather KO, Benjamin DK Jr; Fluconazole Prophylaxis Study Team on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Steering Committee; Fluconazole Prophylaxis Study Team.
    Clinical Infectious Diseases  September 2016, issue 63, volume 5, pages 604-10.
    Pubmed PMID: 27298330; PMCID: PMC4981761 [Free PMC article].
  16. Electronic Health Records and Pharmacokinetic Modeling to Assess the Relationship between Ampicillin Exposure and Seizure Risk in Neonates.
    Hornik CP, Benjamin DK Jr, Smith PB, Pencina MJ, Tremoulet AH, Capparelli EV, Ericson JE, Clark RH, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act—Pediatric Trials Network.
    Journal of Pediatrics August 2016, issue 3476, volume 16, pages 30546-7.
    PubMed PMID: 27522443. PMCID: PMC5085855  [Free access available on 11/1/2017]
  17. Safety of histamine-2 receptor blockers in hospitalized VLBW infants. 
    Romaine A, Ye D, Ao Z, Fang F, Johnson O, Riggs B, Benjamin DK, Cotton CM, Testoni D, Clark RH, Chu V, Smith PB, Hornik CP, Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Early Human Development August 2016, volume 99, pages 27-30.
    PMCID: PMC4969147 [Free PMC article]
  18. Metronidazole Metabolism in Neonates and the Interplay between Ontogeny and Genetic Variation.
    Wang LA, Gonzalez D, Leeder JS, Tyndale RF, Pearce RE, Benjamin DK Jr, Kearns GL, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act-Pediatric Trials Network Steering Committee.
    Journal of Clinical Pharmacology July 2016 [Epub ahead of print].
    Pubmed PMID: 27417511. 
  19. Optimizing Operational Efficiencies in Early Phase Trials: The Pediatric Trials Network Experience
    England A, Wade K, Smith PB, Berezny K, Laughon M, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee
    Contemporary Clinical Trials March 2016, volume 47, pages 376-82. 
    PubMed ID: 26968616. PMCID: PMC4997801  [Free PMC article]
  20. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
    Estepp JH, Melloni C, Thornburg CD, Wiczling P, Rogers Z, Rothman JA, Green NS, Liem R, Brandow AM, Crary SE, Howard TH, Morris MH, Lewandowski A, Garg U, Jusko WJ, Neville KA; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee.
    Journal of Clinical Pharmacology March 2016, volume 56, issue 3, pages 298-306. 
    PMCID: PMC4892120 [Free PMC article]
  21. Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants.
    Gonzalez D, Delmore P, Bloom BT, Cotten CM, Poindexter BB, McGowan E, Shattuck K, Bradford KK, Smith PB, Cohen-Wolkowiez M, Morris M, Yin W, Benjamin DK, Laughon MM, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Steering Committee.
    Antimicrobial Agents and Chemotherapy • April 2016, volume 60, issue 5, pages 2888-94.
    PMCID: PMC4862454 [Free PMC article]
  22. Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants.
    Samiee-Zafarghandy S, Van den Anker JN, Laughon MM, Clark RH, Smith PB, and Hornik CP, Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants, on behalf of the Best Pharmaceuticals for Children’s Act- Pediatric Trials Network Administrative Core Committee
    American Journal of Perinatology • February 1, 2016, volume 36, issue 2, pages 137-140.
    PMCID: PMC4731250 [Free PMC article]
  23. Gaps in Drug Dosing for Obese Children: A Systematic Review of Commonly Prescribed Emergency Care Medications.
    Rowe S, Siegel D, Benjamin DK Jr; Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee.
    Clinical Therapy September 1, 2015, volume 39, issue 9, pages 1924-1932.
    PMCID: PMC4586086 [Free PMC article]
  24. Cefepime and Ceftazidime Safety in Hospitalized Infants.
    Arnold CJ, Ericson JE, Cho N, Tian J, Wilson S, Chu VH, Hornik CP, Clark RH, Benjamin Jr. DK, and Smith PB, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee.
    Pediatric Infectious Disease Journal • September 2015, volume 34, issue 9, pages 964-968.
    PMCID: PMC4573537 [FreePMC article]
  25. Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection. 
    Trachtman H, Frymoyer A, Lewandowski A, Greenbaum LA, Feig DI, Gipson DS, Warady BA, Goebel JW, Schwartz GJ, Lewis K, Anand R, Patel UD; Best Pharmaceuticals for Children Act-Pediatric Trials Network Administrative Core Committee.
    Clinical Pharmacology Therapy • July 2015, volume 98, issue 1, pages 25-33.
    PMCID: PMC4536255 [Free PMC article]
  26. Safety of octreotide in hospitalized infants.
    Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH, Smith PB; Best Pharmaceuticals for Children Act — Pediatric Trials Network Administrative Core Committee.
    Early Human Development • July 2015, volume 91, issue 7, pages 387-392.
    PMCID: PMC4450124 [Free PMC article]
  27. Simultaneous determination of trimethoprim and sulfamethoxazole in dried plasma and urine spots.
    Gonzalez D, Melloni C, Poindexter BB, Yogev R, Atz AM, Sullivan JE, Mendley SR, Delmore P, Delinsky A, Zimmerman K, Lewandowski A, Harper B, Lewis KC, Benjamin DK Jr, Cohen-Wolkowiez M; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee.
    Bioanalysis • May 2015, volume 7, issue 9, pages 1137-149.
    PMCID: PMC4455038 [Free PMC article]
  28. Drug dosing and pharmacokinetics in children with obesity: a systematic review.
    Harskamp-van Ginkel MW, Hill KD, Becker K, Testoni D, Cohen-Wolkowiez M, Gonzalez D, Barrett JS, Benjamin DK Jr., Siegel DA, Banks P, Watt KM; for the Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee.
    JAMA Pediatrics • May 2015, volume 169, issue 7, pages 678-685.
    PMCID: PMC4494887 [Free PMC article]
  29. Use and safety of erythromycin and metoclopramide in hospitalized infants.
    Ericson JE, Arnold C, Cheeseman J, Cho J, Kaneko S, Wilson E, Clark RH, Benjamin DK Jr, Chu V, Smith PB, Hornik CP; Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee.
    Journal of Pediatric Gastroenterology and Nutrition • March 2015, volume 61, issue 3, pages 334-339.
    PubMed Central ID (PMCID): PMC4553109 [Free PMC article]
  30. Rifampin use and safety in hospitalized infants.
    Arnold CJ, Ericson J, Kohman J, Corey KL, Oh M, Onabanjo J, Hornik CP, Clark RH, Benjamin DK Jr, Smith PB, Chu VH; on behalf of the Best Pharmaceuticals for Children Act–Pediatric Trials Network Administrative Core Committee.
    American Journal of Perinatology • January 2015, issue 32, volume 6, pages 565-570.
    PMCID: PMC4433596 [Free PMC article]
  31. Anaerobic antimicrobial therapy after necrotizing enterocolitis in VLBW infants.
    Autmizguine J, Hornik CP, Benjamin DK Jr, Laughon MM, Clark RH, Cotten CM, Cohen-Wolkowiez M, Benjamin DK, Smith PB; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee.
    Pediatrics • January 2015, volume 135, issue 1, pages e117-e125.
    PMCID: PMC4279070 [Free PMC article]
  32. Safety of milrinone use in neonatal intensive care units.
    Samiee-Zafarghandy S, Raman SR, van den Anker JN, McHutchison K, Hornik CP, Clark RH, Brian Smith P; Best Pharmaceuticals for Children Act—Pediatric Trials Network Administrative Core Committee.
    Early Human Development • January 2015, volume 91, issue 1, pages 31-35.
    PMCID: PMC4302030 [Free PMC article]
  33. Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents.
    Gonzalez D, Melloni C, Yogev R, Poindexter BB, Mendley SR, Delmore P, Sullivan JE, Autmizguine J, Lewandowski A, Harper B, Watt KM, Lewis KC, Capparelli EV, Benjamin DK Jr, Cohen-Wolkowiez M.
    Clinical Pharmacology and Therapeutics • October 2014, volume 96, issue 4, pages 429-437.
    PMCID: PMC4169790 [Free PMC article]
  34. Characterization of the population pharmacokinetics of ampicillin in neonates using an opportunistic study design.
    Tremoulet A, Le J, Poindexter B, Sullivan JE, Laughon M, Delmore P, Salgado A, Chong SI, Melloni C, Gao J, Benjamin DK Jr, Capparelli EV, Cohen-Wolkowiez M; on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act — Pediatric Trials Network.
    Antimicrobial Agents and Chemotherapy • June 2014, volume 58, issue 6, pages 3013-3020.
    PMCID: PMC4068432 [Free PMC article]
  35. Effect of fluconazole prophylaxis on candidiasis and mortality in premature infants: a randomized clinical trial.
    Benjamin DK Jr, Hudak ML, Duara S, Randolph DA, Bidegain M, Mundakel GT, Natarajan G, Burchfield DJ, White RD, Shattuck KE, Neu N, Bendel CM, Kim MR, Finer NN, Stewart DL, Arrieta AC, Wade KC, Kaufman DA, Manzoni P, Prather KO, Testoni D, Berezny KY, Smith PB; Fluconazole Prophylaxis Study Team.
    JAMA • May 7, 2014, volume 311, issue 17, pages 1742-1749.
    PMCID: PMC4110724 [Free PMC article]
  36. Population pharmacokinetics of intravenous acyclovir in preterm and term infants.
    Sampson MR, Bloom BT, Lenfestey RW, Harper B, Kashuba AD, Anand R, Benjamin DK Jr, Capparelli E, Cohen-Wolkowiez M, Smith PB.
    Pediatric Infectious Diseases Journal • January 2014, volume 33, issue 1, pages 42-49.
    PMCID: PMC3904301 [Free PMC article]
  37. Intestinal fatty-acid binding protein and metronidazole response in premature infants.
    Sampson MR, Bloom BT, Arrieta A, Capparelli E, Benjamin DK Jr, Smith PB, Kearns GL, van den Anker J, Cohen-Wolkowiez M.
    Journal of Neonatal and Perinatal Medicine • January 2014, volume 7, issue 3, pages 223-228.
    PMCID: PMC4225165 [Free PMC article]
  38. Evaluation of the Mercy TAPE: performance against the standard for pediatric weight estimation.
    Abdel-Rahman SM, Paul IM, James LP, Lewandowski A; Best Pharmaceuticals for Children Act-Pediatric Trials Network.
    Annals of Emergency Medicine • October 2013, volume 62, issue 4, pages 332-339.
    PMCID: PMC4039210 [Free PMC article]
  39. Determining population and developmental pharmacokinetics of metronidazole using plasma and dried blood spot samples from premature infants.
    Cohen-Wolkowiez M, Sampson M, Bloom BT, Arrieta A, Wynn JL, Martz K, Harper B, Kearns GL, Capparelli EV, Siegel D, Benjamin DK Jr, Smith PB; on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Pediatric Infectious Diseases Journal • September 2013, volume 32, issue 9, pages 956-961.
    PMCID: PMC3769518 [Free PMC article]
  40. Adverse events associated with meropenem versus imipenem/cilastatin therapy in a large retrospective cohort of hospitalized infants.
    Hornik CP, Herring AH, Benjamin DK Jr, Capparelli EV, Kearns GL, van den Anker J, Cohen-Wolkowiez M, Clark RH, Smith PB; Best Pharmaceuticals for Children Act-Pediatric Trials Network.
    Pediatric Infectious Diseases Journal • July 2013, volume 32, issue 7, pages 748-753.
    PMCID: PMC3708263 [Free PMC article]
  41. Safety and effectiveness of meropenem in infants with suspected or complicated intra-abdominal infections.
    Cohen-Wolkowiez M, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Randolph DA, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Rich W, Brozanski BS, van den Anker J, Blumer J, Laughon M, Watt KM, Kearns GL, Capparelli EV, Martz K, Berezny K, Benjamin DK Jr, Smith PB; on behalf of the Meropenem Study Team.
    Clinical Infectious Disease • December 2012, volume 55, number 11, pages 1495-1502.
    PMCID: PMC3491861 [Free PMC article]
  42. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections.
    Smith PB, Cohen-Wolkowiez M, Castro LM, Poindexter B, Bidegain M, Weitkamp JH, Schelonka RL, Ward RM, Wade K, Valencia G, Burchfield D, Arrieta A, Bhatt-Mehta V, Walsh M, Kantak A, Rasmussen M, Sullivan JE, Finer N, Brozanski BS, Sanchez P, van den Anker J, Blumer J, Kearns GL, Capparelli EV, Anand R, Benjamin DK Jr; Meropenem Study Team.
    The Pediatric Infectious Disease Journal • October 2011, volume 30, number 10, pages 844-849.
    PMCID: PMC3173561 [Free PMC article]


Publications and Presentations Supported by the Pediatric Trials Network

Publications

  1. Population Pharmacokinetics of Fluconazole in Premature Infants with Birth Weights Less than 750 Grams.
    Momper JD, Capparelli EV, Wade KC, Kantak A, Dhanireddy R, Cummings JJ, Nedrelow JH, Hudak ML, Mundakel GT, Natarajan G, Gao J, Laughon M, Smith PB, Benjamin DK Jr.
    Antimicrobial Agents and Chemotherapy • August 2016, volume 60, issue 9, pages 5539‐45.
    PMCID: PMC4997840 [Free PMC article]
  2. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive candidiasis in children supported with extracorporeal membrane oxygenation.
    Watt KM, Gonzalez D, Benjamin DK Jr, Brouwer KL, Wade KC, Capparelli E, Barrett J, Cohen-Wolkowiez M.
    Antimicrobial Agents and Chemotherapy • July 2014, volume 59, issue 7, pages 3935-43.
    PMCID: PMC4468733 [Free PMC article]
  3. Editorial commentary: Fluconazole therapeutic drug monitoring in children with cancer: not today.
    Cohen-Wolkowiez M, Benjamin DK Jr.
    Clinical Infectious Diseases • December 2014, volume 59, issue 11, pages 1534-1536.
    Free access available.
  4. Medication use in the neonatal intensive care unit.
    Hsieh EM, Hornik CP, Clark RH, Laughon MM, Benjamin DK Jr, Smith PB; Best Pharmaceuticals for Children Act—Pediatric Trials Network.
    American Journal of Perinatology • October 2014, volume 31, issue 9, pages 811-821.
    PMCID: PMC4061287 [Free PMC article]
  5. Pharmacokinetics of antimicrobials in obese children.
    Sampson MR, Cohen-Wolkowiez M, Benjamin DK Jr., Capparelli E, Watt KM, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
    Generics and Biosimilars Initiative Journal (GaBI Journal) • October 2013, volume 2, issue 2, pages 76-81.
    PMCID: PMC4084753 [Free PMC article]
  6. Comparative effectiveness of 3 surfactant preparations in premature infants.
    Trembath A, Hornik CP, Clark R, Smith PB, Daniels J, Laughon M; Best Pharmaceuticals for Children Act—Pediatric Trials Network.
    Journal of Pediatrics • October 2013, volume 163, issue 4, pages 955-960.
    PMCID: PMC3779477 [Free PMC article]
  7. Innovative clinical trial design for pediatric therapeutics.
    Laughon MM, Benjamin DK Jr, Capparelli EV, Kearns GL, Berezny K, Paul IM, Wade K, Barrett J, Smith PB, Cohen-Wolkowiez M.
    Expert Review of Clinical Pharmacology • September 2011, volume 4, number 5, pages 643-652.
    PMCID: PMC3184526 [Free PMC article]

Presentations

International Society for the Study of Vascular Anomalies, May 29 – June 1, 2018

  1. Systemic Timolol Exposures Following Topical Application to Infantile Hemangiomas. B Drolet, F Boakye-Agyeman, S Chamlin, S Denne, A Haggstrom, B Harper, K Holland, JH Lee, HM Liew, A Lewandowski, C Gelber, A Mancini, D Siegel, N Stefanko, R Yogev, and C Melloni on behalf of the Pediatric Trials Network Steering Committee.

Pediatric Academic Societies Annual Meeting, May 5-8, 2018

  1. Dose-Safety Relationship for Acyclovir in the Treatment of Neonatal Herpes Simplex Virus. J Ericson, DK Benjamin Jr, F Boakye-Agyeman, F Raiola, F Adler-Shohet, M Laughon, B Poindexter, E Payne, J Zhao, K Kaneshige, B Harper, and PB Smith on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  2. Hospital Associated and Ventilator Acquired Bacterial Pneumonia in Infants and Children. J Ericson, J Bradley, J McGuire, M Michaels, A Schwarz, R Frenck, J Deville, S Agarwal, A Bressler, J Gao, T Spears, DK Benjamin Jr, and PB Smith on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  3. Development of an Electronic Health Record Derived Multicenter Inpatient Pediatric Data Repository. CP Hornik, AM Atz, C Bendel, F Chan, K Downes, R Grundmeier, B Fogel, D Gipson, M Laughon, M Miller, M Smith, C Livingston, C Kluchar, A Heath, R McDonald, C Jarrett, B McKerlie, H Patel, and C Hunter on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  4. Population Pharmacokinetics of Milrinone in Infants and Children. CP Hornik, R Yogev, P Mourani, K Watt, J Sullivan, AM Atz, D Speicher, A Al-Uzri, M Adu-Darko, A Lewandowski, C Gelber, S Lin, B Harper, C Melloni, M Cohen-Wolkowiez, and D Gonzalez on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  5. Correlating Pulmonary Hypertension by Echocardiogram with Mortality in Premature Infants. R Torok, P Barker, A McCrary, T Spears, CP Hornik, and M Laughon on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  6. Validation and Human Factors Evaluation of a New Device for Infant Weight Estimation. S Abdel-Rahman, I Paul, P Delmore, J Chen, G Sharma, J Debski, M Mills, DK Benjamin Jr, CP Hornik, PB Smith, and R Greenberg on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  7. Weight Gain and Metabolic Syndrome in Children Exposed to Second-Generation Antipsychotic Medications. A Czaja, A Fiks, CP Hornik, C Livingston, L Berrigan, L Song, J Steffes, W Bilker, and R Grundmeier on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  8. Impact of Personal Protective Equipment on Pediatric CPR Performance. A Donoghue, G Good, M Kou, C Eiger, D Siegel, M Nash, F Henretig, H Stacks, CP Hornik, A Kochman, L Gosnell, M Ushay, J Debski, G Sharma, A Lewandowski, J Chen, S Krug, and M Adler on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  9. The Use of PPE During Pediatric Resuscitation: Which Tasks Are Most Affected? The Results of a Survey During a Simulation Trial. G Good, A Donoghue, M Kou, C Eiger, D Siegel, M Nash, F Henretig, CP Hornik, H Stacks, A Kochman, L Gosnell, J Chen, A Lewandowski, S Krug, and M Adler on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  10. Population Pharmacokinetics and Safety of Sildenafil in Premature Infants. D Gonzalez, M Laughon, PB Smith, S Ge, N Ambalavanan, AM Atz, G Sokol, CD Hornik, D Stewart, G Mundakel, M Mills, M Cohen-Wolkowiez, K Martz, and CP Hornik on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.

Pediatric Academic Societies Annual Meeting, May 6-9, 2017

  1. Developmental Pharmacokinetics of Methadone from Infants to Adolescents. KM Watt, L Lam, S Hupp, AM Atz, J Lowry, V Bhatt-Mehta, A Fernandez, M Morris, A Lewandowski, J Zhao, M Cohen-Wolkowiez, and E Capparelli on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  2. Population Pharmacokinetics of Trimethoprim/Sulfamethoxazole in Infants and Children. J Autmizguine, C Melloni, C Hornik, S Dallefeld, B Harper, R Yogev, J Sullivan, AM Atz, A Al-Uzri, S Mendley, B Poindexter, A Lewandowski, P Delmore, M Cohen-Wolkowiez, and D Gonzalez on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  3. Safety of Off-Label Use of Caffeine Citrate in Premature Infants. M Puia Dumitrescu, PB Smith, J Zhao, A Soriano, M Morris, E Bendel-Stenzal, F Moya, R Chhabra, M Laughon, and K Wade on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network. (Abstract)
  4. Effect of Fluconazole Prophylaxis on Fluconazole Candida Susceptibility in Premature Infants. J Autmizguine, PB Smith, K Prather, C Bendel, G Natarajan, D Kaufman, W Schell, J Gao, and D Benjamin on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.

Pediatric Academic Societies Annual Meeting, April 30-May 3, 2016

  1. Dosing of antimicrobials in the neonatal in the NICU: Does clinical practice reflect published recommendations?
    M England, RG Greenberg, RH Clark, M Laughon, M Cohen-Wolkowiez, DK Benjamin Jr, and PB Smith on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.
  2. Use of Pediatric and Adult Midazolam Population Pharmacokinetics to Assess IM Dosing and Early Drug Exposure for Status Epilepticus.
    E Capparelli, K Chiswell, B Smith, D Siegel, S Weinstein, S Muchohi,  M Reed, J Barrett,  S de Wildt, E Jaqc-Aigrain, J Ma, T Glauser for the Pediatric Trials Network.
  3. Using Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin Safety in Infants.
    S Salerno, C Hornik, M Cohen-Wolkowiez, PB Smith, R Clark, and D Gonzalez on behalf of the Administrative Core Committee of the Best Pharmaceuticals for Children Act – Pediatric Trials Network.

Pediatric Academic Societies Annual Meeting, April 25-28, 2015

  1. Population Pharmacokinetics of Fluconazole in Extremely Low Birth Weight Infants.
    Momper JD, Capparelli EV, Wade KC, Natarajan G, Gao J, Laughon M, Smith PB, Benjamin DK Jr, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network
  2. Pharmacokinetics of Multiple-Dose Intravenous Clindamycin in Obese Children
    Smith MJ, Gonzalez D, Goldman JL, Yogev R, Sullivan JE, Reed MD, Anand R, Martz K, Berezny KY, Smith PB, Cohen-Wolkowiez M, Watt K, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network
  3. Safety of High-Dose Acyclovir in Infants
    Ericson JE, Gostelow M, Autmizguine J, Clark RH, Benjamin DK Jr, Hornik CP, Smith PB, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network Administrative Core Committee
  4. Effectiveness of G-CSF in Hospitalized Infants
    Ericson JE, Lee JA, Sauer B, Tuminski W, Cheong J, Fitz-Henley J, Mayers M, Ezuma-Igwe C, Hornik CP, Clark RH, Benjamin DK Jr., Chu V, Smith PB, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network
  5. Safety of Enalapril in Infants Admitted to the Neonatal Intensive Care Unit
    Ku LC, Benjamin DK, Clark RH, Hornik CP, Smith PB, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network

Pediatric Academic Societies Annual Meeting, May 3-6, 2014

  1. Ampicillin Exposure and Odds of Seizures in a Large Cohort of Hospitalized Neonates
    Hornik CP, Benjamin DK Jr., Clark RH, Capparelli EV, Le J, Tremoulet A, Cohen-Wolkowiez M, Smith PB, for the Best Pharmaceuticals for Children Act–Pediatric Trials Network
  2. Safety of Octreotide in Hospitalized Infants
    Testoni D, Hornik CP, Neely ML, Yang Q, McMahon AW, Clark RH, Smith PB, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network
  3. Evaluation of the BPCA Priority List
    Gostelow M, Tripathi N, Benjamin DK Jr., Benjamin DK, Cohen-Wolkowiez M, Clark RH, Laughon MM, Smith PB, on behalf of the Best Pharmaceuticals for Children Act – Pediatric Trials Network

Pediatric Academic Societies Annual Meeting, May 4-7, 2013

  1. The Mercy TAPE: A New Device for Pediatric Weight Estimation
    Paul I, James L, Lewandowski A, Abdel-Rahman S
  2. Ampicillin Safety in Hospitalized Infants
    Hornik CP, Van Ginkel MW, Benjamin Jr, DK, Cohen-Wolkowiez M, Smith PB
  3. Drug Dosing in Obese Children
    Van Ginkel MW, Becker K, Cohen-Wolkowiez M, Smith PB, Barrett JS, Benjamin Jr., Watt KM
  4. Population Pharmacokinetics of Acyclovir in Preterm and Term Infants
    Sampson MR, Bloom BT, Anand R, Benjamin Jr., DK, Capparelli E, Cohen-Wolkowiez M, Smith PB, Lenfestey RW

Pediatric Academic Societies Annual Meeting, April 28-May 1, 2012

  1. Population Pharmacokinetics of Acyclovir in Preterm and Term Infants
    Krystle Perez, Kim Chantala, Amy H. Herring, P. Brian Smith, Reese H. Clark, Daniel K. Benjamin Jr., Michael Cohen-Wolkowiez, Matthew Laughon
  2. Safety of Acyclovir in Hospitalized Infants
    Simon B. Ascher, Daniel K. Benjamin Jr., C. Michael Cotten, Christoph P. Hornik, Michael Cohen-Wolkowiez, Reese H. Clark, and P. Brian Smith
  3. Comparative Effectiveness of Three Surfactant Preparations in Premature Infants
    Andrea Trembath, Christoph P. Hornik, Reese H. Clark, P. Brian Smith, Matthew Laughon, Michelle Beitzel

American Society for Clinical Pharmacology and Therapeutics, March 12-17, 2012

  1. Pediatric Trials Network: Optimizing Pediatric Clinical Trial Design
    Daniel K. Benjamin Jr.
  2. Pediatric Trials Network: Optimizing Pediatric Clinical Trial Design
    Mario Sampson


Other Articles of Interest

  1. Drug labeling and exposure in neonates.
    Laughon MM, Avant D, Tripathi N, Hornik CP, Cohen-Wolkowiez M, Clark RH, Smith PB, Rodriguez W.
    JAMA Pediatrics • February 2014, volume 168, issue 2, pages 130-136.
    PMCID: PMC3927948 [Free PMC article]
  2. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective.
    Lestner JM, Smith PB, Cohen-Wolkowiez M, Benjamin DK Jr, Hope WW.
    British Journal of Clinical Pharmacology • June 2013, volume 75, issue 6, pages 1381-1395.
    PMCID: PMC3690098 [Free PMC article]
  3. Proton pump inhibitors in pediatrics: mechanism of action, pharmacokinetics, pharmacogenetics, and pharmacodynamics.
    Ward RM, Kearns GL.
    Paediatric Drugs • April 2013, volume 15, issue 2, pages 119-131.
    PMCID: PMC3616221 [Free PMC article]
  4. Urinary tract infection concordance with positive blood and cerebrospinal fluid cultures in the neonatal intensive care unit.
    Downey LC, Benjamin DK Jr, Clark RH, Watt KM, Hornik CP, Laughon MM, Cohen-Wolkowiez M, Smith PB.
    Journal of Perinatology • April 2013, volume 33, issue 4, pages 302-306.
    PMCID: PMC3549035 [Free PMC article]
  5. Use of pharmacokinetic modeling to individualize FFP dosing in factor V deficiency.
    Shakhnovich V, Daniel J, Wicklund B, Kearns G, Neville K.
    Haemophilia • March 2013, volume 19, number 2, pages 251-255.
  6. Risk factors for invasive candidiasis in infants >1500 g birth weight.
    Lee JH, Hornik CP, Benjamin DK Jr, Herring AH, Clark RH, Cohen-Wolkowiez M, Smith PB.
    The Pediatric Infectious Disease Journal • March 2013, volume 32, issue 3, pages 222-226.
    PMCID: PMC3578110 [Free PMC article]
  7. Group B Streptococcus and Escherichia coli infections in infants in the intensive care nursery in the era of intrapartum antibiotic prophylaxis.
    Bauserman MS, Laughon MM, Hornik CP, Smith PB, Benjamin DK Jr, Clark RH, Engmann C, Cohen-Wolkowiez M.
    The Pediatric Infectious Disease Journal • March 2013, volume 32, issue 3, pages 208-212.
    PMCID: PMC3572304 [Free PMC article]
  8. Triazole use in the nursery: fluconazole, voriconazole, posaconazole, and ravuconazole.
    Watt K, Manzoni P, Cohen-Wolkowiez M, Rizzollo S, Boano E, Jacqz-Aigrain E, Benjamin DK.
    Current Drug Metabolism • February 2013, volume 14, issue 2, pages 193-202.
    PMCID: PMC3541435 [Free PMC article]
  9. Pharmacokinetics of single-dose doripenem in adults with cystic fibrosis.
    Cirillo I, Vaccaro N, Redman R, Black PL, Kearns GL.
    Journal of Clinical Pharmacology • November 2012, volume 52, number 11, pages 1645-1653.
  10. Interpreting pharmacogenetic data in the developing neonate: the challenge of hitting a moving target.
    Leeder JS, Kearns GL.
    Clinical Pharmacology and Therapeutics • October 2012, volume 92, pages 434-436.
  11. Pharmacokinetics and safety of fluconazole in infants supported with extracorporeal membrane oxygenation.
    Watt KM, Benjamin DK Jr., Cheifetz IM, Moorthy G, Wade KC, Smith PB, Brouwer KLR, Capparelli EV, Cohen-Wolkowiez M.
    The Pediatric Infectious Disease Journal • October 2012, volume 31, number 10, pages 1042-1047.
    PMCID: PMC3444624 [Free PMC article]
  12. Pharmacokinetics and tolerability of single-dose daptomycin in young infants.
    Cohen-Wolkowiez M, Watt KM, Hornik CP, Benjamin DK Jr., Smith PB.
    The Pediatric Infectious Disease Journal • September 2012, volume 31, number 9, pages 935-937.
    PMCID: PMC3421038 [Free PMC article]
  13. Failure of proton pump inhibitors to treat GERD in neonates and infants: a question of drug, diagnosis or design.
    Shakhnovich V, Ward RM, Kearns GL.
    Clinical Pharmacology and Therapeutics • September 2012, volume 92, pages 388-392.
  14. Empirical antifungal therapy and outcomes in extremely-low-birth-weight infants with invasive candidiasis.
    Greenberg RG, Benjamin DK Jr., Gantz MG, Cotton CM, Stoll BJ, Walsh MC, Sánchez PJ, Shankaran S, Das A, Higgins RD, Miller NA, Auten KJ, Walsh TJ, Laptook AR, Carlo WA, Kennedy KA, Finer NN, Duara S, Schibler K, Ehrenkranz RA, Van Meurs KP, Frantz III ID, Phelps DL, Poindexter BB, Bell EF, O’Shea TM, Watterberg KL, Goldberg RN, Smith PB, for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.
    Journal of Pediatrics • August 2012, volume 161, number 2, pages 264-269.
    PMCID: PMC3380169 [Free PMC article]
  15. Fluconazole pharmacokinetics and safety in premature infants.
    Turner K, Manzoni P, Benjamin DK, Cohen-Wolkowiez M, Smith PB, Laughon MM.
    Current Medicinal Chemistry • 2012, volume 19, number 27, pages 4617-4620.
    PMCID: PMC3522083 [Free PMC article]
  16. Antihypertensive drug use by children: are the drugs labeled and indicated?
    Welch WP, Yang W, Taylor-Zapata P, Flynn JT.
    Journal of Clinical Hypertension (Greenwich) • June 2012, volume 14, number 6, pages 388-395.
    PMCID: PMC3375915 [Free PMC article]
  17. Population pharmacokinetics of piperacillin using scavenged samples from premature infants.
    Cohen-Wolkowiez M, Benjamin DK Jr., Ross A, James LP, Sullivan JE, Walsh M, Zadell A, Newman N, White NR, Kashuba ADM, Ouellet D.
    Therapeutic Drug Monitoring • June 2012, volume 34, number 3, pages 312-319.
    PMCID: PMC3354042 [Free PMC article]
  18. Pediatric antifungal drug development: lessons learned and recommendations for the future.
    Watt KM, Cohen-Wolkowiez M, Ward RM, Benjamin DK Jr.
    The Pediatric Infectious Disease Journal • June 2012, volume 31, number 6, pages 635-637.
    PMCID: PMC3356443 [Free PMC article]
  19. Therapeutic monitoring of voriconazole in children less than 3 years of age: a case report and summary of voriconazole concentrations for 10 children.
    Doby EH, Benjamin DK Jr, Blaschke AJ, Ward RM, Pavia AT, Martin PL, Driscoll TA, Cohen-Wolkowiez M, Moran C.
    The Pediatric Infectious Disease Journal • June 2012, volume 31, number 6, pages 623-635.
    PMCID: PMC3356483 [Free PMC article]
  20. Neonatal fungal infections: when to treat?
    Hsieh E, Smith PB, Jacqz-Aigrain E, Kaguelidou F, Cohen-Wolkowiez M, Manzoni P, Benjamin DK Jr.
    Early Human Development • May 2012, volume 88, supplement 2, pages S6-S10.
    PMCID: PMC3512570 [Free PMC article]
  21. Antifungal therapy and outcomes in infants with invasive Candida infections.
    Ascher SB, Smith PB, Watt K, Benjamin DK, Cohen-Wolkowiez M, Clark RH, MD, Benjamin DK Jr., Moran C.
    Pediatric Infectious Disease Journal • May 2012, volume 31, number 5, pages 439-443.
    PMCID: PMC3329577 [Free PMC article]
  22. Population pharmacokinetics of metronidazole using scavenged samples from preterm infants.
    Cohen-Wolkowiez M, Ouellet D, Smith PB, James LP, Ross A, Sullivan JE, Walsh MC, Zadell A, Newman N, White NR, Kashuba AD, Benjamin DK Jr.
    Antimicrobial Agents and Chemotherapy • April 2012, volume 56, number 4, pages 1828-1837.
    PMCID: PMC3318328 [Free PMC article]
  23. Methicillin-resistant and susceptible Staphylococcus aureus bacteremia and meningitis in preterm infants.
    Shane AL, Hansen NI, Stoll BJ, Bell EF, Sánchez PJ, Shankaran S, Laptook AR, Das A, Walsh MC, Hale EC, Newman NS, Schrag SJ, Higgins RD; for the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network.
    Pediatrics • April 2012, volume 129, number 4, pages e914-e922.
    PMCID: PMC3313632 [Free PMC article]
  24. Infliximab clearance in children: potential association with resting energy expenditure.
    Goldman JL, Davis HM, Zhou H, Kearns GL.
    Annals of Paediatric Rheumatology • February 2012, volume 1, pages 120-125.
  25. Pharmacokinetics of moxifloxacin in an infant with Mycoplasma hominis meningitis.
    Watt KM, Massaro MM, Smith B, Cohen-Wolkowiez M, Benjamin DK Jr, Laughon MM.
    The Pediatric Infectious Disease Journal • February 2012, volume 31, number 2, pages 197-199.
    PMCID: PMC3358780 [Free PMC article]
  26. The status of paediatric medicines initiatives around the world—what has happened and what has not?
    Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, Peterson RG, Sri Ranganathan S, de Wildt SN.
    European Journal of Clinical Pharmacology • January 2012, volume 68, pages 1–10.
  27. Development of a liquid chromatography-tandem mass spectrometry assay of six antimicrobials in plasma for pharmacokinetic studies in premature infants.
    Cohen-Wolkowiez M, White NR, Bridges A, Benjamin DK Jr, Kashuba AD.
    Journal of Chromatography B • November 15, 2011, volume 879, number 30, pages 3497-3506.
    PMCID: PMC3210405 [Free PMC article]
  28. Clinical pharmacology as a foundation for translational science.
    Waldman SA, Hohl RJ, Kearns GL, Swan SJ, Terzic A.
    Clinical Pharmacology and Therapeutics • July 2011, volume 90, number 1, pages 10–13.
  29. A multicenter, randomized, open-label, pharmacokinetics and safety study of pantoprazole tablets in children and adolescents aged 6 through 16 years with gastroesophageal reflux disease.
    Ward RM, Kearns GL, Tammara B, Bishop P, O’Gorman MA, James LP, Katz MH, Maguire MK, Rath N, Meng X, Comer GM.
    Journal of Clinical Pharmacology • June 2011, volume 51, number 6, pages 876–887.
    PMCID: PMC3190583 [Free PMC article]
  30. Fluconazole loading dose pharmacokinetics and safety in infants.
    Piper L, Smith PB, Hornik CP, Cheifetz IM, Barrett JS, Moorthy G, Hope WW, Wade KC, Cohen-Wolkowiez M, Benjamin DK Jr.
    The Pediatric Infectious Disease Journal • May 2011, volume 30, number 5, pages 375-378.
    PMCID: PMC3078721 [Free PMC article]
  31. Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates.
    Cohen-Wolkowiez M, Benjamin DK Jr, Piper L, Cheifetz IM, Moran C, Liu P, Aram J, Kashuba AD, Capparelli E, Walsh TJ, Hope WW, Smith PB.
    Clinical Pharmacology & Therapeutics • May 2011, volume 89, number 5, pages 702-707.
    PMCID: PMC3124385 [Free PMC article]
  32. Developmental pharmacogenomics.
    Neville KA, Becker ML, Goldman JL, Kearns GL.
    Paediatric Anaesthesia • March 2011, volume 21, number 3, pages 255–265.
  33. Histamine: new thoughts about a familiar mediator.
    Jones BL, Kearns GL.
    Clinical Pharmacology and Therapeutics • February 2011, volume 89, number 2, pages 189-197.
  34. Pharmacologic considerations for oseltamivir disposition: focus on the neonate and young infant.
    Abdel-Rahman SM, Newland JG, Kearns GL.
    Paediatric Drugs • February 2011, volume 13, number 1, pages 19-31.
  35. Developmental pharmacokinetics.
    van den Anker JN, Schwab M, Kearns GL.
    Handbook of Experimental Pharmacology • 2011, volume 205, pages 51–75.
  36. Beyond biomarkers: an opportunity to address the ‘pharmacodynamic gap’ in pediatric drug development.
    Kearns GL.
    Biomarkers in Medicine • December 2010, volume 4, number 6, pages 783–786.
  37. Pharmacokinetics and tolerability of single-dose intravenous ertapenem in infants, children, and adolescents.
    Abdel-Rahman SM, Kearns GL, Topelberg S, Jacobs RF, Mistry GC, Majumdar A, et al.
    The Pediatric Infectious Disease Journal • December 2010, volume 29, pages 1072–1076.
    PMCID: PMC2991518 [Free PMC article]
  38. Understanding the relative roles of pharmacogenetics and ontogeny in pediatric drug development and regulatory science.
    Leeder JS, Kearns GL, Spielberg SP, van den Anker J.
    Journal of Clinical Pharmacology • December 2010, volume 50, pages 1377–1387.
  39. Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.
    Kearns GL, Leeder JS, Gaedigk A.
    Drug Metabolism and Disposition • June 2010, volume 38, number 6, pages 894–897.
    PMCID: PMC2879959 [Free PMC article]
  40. Pharmacokinetics and drug dosing in obese children.
    Kendrick JG, Carr RR, Ensom MHH
    The Journal of Pediatric Pharmacology and Therapeutics • April-June 2010, volume 15, number 2, pages 94-109.
    PMCID: PMC3018176 [Free PMC article]
  41. Ontogeny of midazolam glucuronidation in preterm infants.
    de Wildt SN, Kearns GL, Murry DJ, Koren G, van den Anker JN.
    European Journal of Clinical Pharmacology • February 2010, volume 66, number 2, pages 165–170.
    PMCID: PMC2805794 [Free PMC article]

 

Results icon

results

quote box1

From premature infants to adolescents, PTN generates evidence to take the guesswork out of dosing commonly used medications.